

First Description of *mcr-1*-Mediated Colistin Resistance in Human Infections Caused by *Escherichia coli* in Latin America

Melina Rapoport,^a Diego Faccione,^a Fernando Pasteran,^a Paola Ceriana,^a Ezequiel Albornoz,^a Alejandro Petroni,^a the MCR Group,[‡] Alejandra Corso^a

Servicio Antimicrobianos, National and Regional Reference Laboratory in Antimicrobial Resistance, Instituto Nacional de Enfermedades Infecciosas (INEI)-ANLIS Dr. C. Malbran, Buenos Aires, Argentina^a

Yi-Yun Liu and colleagues recently reported the emergence of plasmid-mediated colistin resistance in China, raising great concern around the world (1–5). The *mcr-1* gene was originally detected in commensal *Escherichia coli* from pigs but was immediately associated with other *Enterobacteriaceae* species of farm animal, meat, and human origins (1–5). A previous study reported short-term intestinal colonization in travelers to South America, suggesting the presence of the *mcr-1* gene in the region (4). In this report, we describe the detection of *mcr-1* in *E. coli* isolates causing human infections in Argentina.

A selection of 87 colistin-resistant clinical isolates submitted to the National Reference Laboratory in Antimicrobial Resistance (NRLAR) from 2008 to January 2016 were screened for *mcr-1* by PCR and Sanger sequencing. The collection included 28 *E. coli* isolates, 19 *Klebsiella pneumoniae* isolates, 36 isolates of other members of the family *Enterobacteriaceae*, and 4 isolates of nonfermenter Gram-negative bacilli. The *mcr-1* gene was detected in nine *E. coli* isolates recovered from nine patients admitted to six hospitals in three cities (Table 1). The average age of the patients was 68.5 (range, 53 to 93) years, and six of them were male. In five patients, *mcr-1*-positive *E. coli* isolates were associated with severe infections (Table 1). All nine *E. coli* isolates were genetically unrelated, as assessed by XbaI pulsed-field gel electrophoresis. *mcr-1*-mediated colistin resistance was successfully transferred by conjugation to a laboratory *Salmonella* strain; no other resistance was cotransferred. Four of the nine *E. coli* isolates coproduced different CTX-M variants (Table 1).

Given reports indicating discrepancies in the determination of the MICs of polymyxins (6), we assessed phenotypic methodologies used to detect *mcr-1*-mediated colistin resistance, i.e., agar dilution according to CLSI guidelines and Etest (bioMérieux), Vitek2C (bioMérieux), the BD Phoenix System (Becton Dickinson), and Sensititre (TREK Diagnostic Systems), by following the manufacturers' recommendations. Colistin MICs were interpreted according to EUCAST (resistance, >2 µg/ml). The nine *mcr-1*-positive *E. coli* isolates were resistant to colistin by all of the MIC methodologies; the MICs ranged from 4 to 16 µg/ml (Table 1). For the remaining 78 *mcr-1*-negative, colistin-resistant *E. coli* isolates, the colistin MICs ranged from 8 to >64 µg/ml (agar dilution; data not shown). The polymyxin B MICs determined by agar dilution mimic those of colistin (8 to 16 µg/ml). Although the disk diffusion method (10-µg colistin disk) is not standardized for polymyxins, all nine *E. coli* isolates carrying the *mcr-1* gene displayed colistin inhibition zones of ≤11 mm. Nevertheless, molecular detection is the gold standard for *mcr-1* identification.

These isolates represent the first confirmed Latin American *mcr-1*-positive clinical isolates, highlighting the widespread

potential of this mechanism. Until now, *mcr-1*-positive isolates have been found sporadically in humans and associated with invasive and noninvasive diseases (5). However, in our country, *mcr-1*-positive *E. coli* isolates were found mostly in invasive infections, suggesting fitness for the hospital environment. The isolates harboring the *mcr-1* gene were genetically unrelated, and the mechanism was horizontally transferable. The available MIC measurement methodologies consistently detected *mcr-1*-positive *E. coli* isolates. Since 2010, the epidemiology of our country has changed drastically, especially driven by the dissemination of *K. pneumoniae* carbapenemase-producing *K. pneumoniae* ST258, other members of the family *Enterobacteriaceae* (7), and also extremely drug-resistant *Acinetobacter baumannii*. This situation was caused by the massive use of polymyxins as part of double- or triple-combination therapy schemes for severe infections. According to the National Surveillance on Antimicrobial Resistance conducted by the WHONET-Argentina Network (90 laboratories), colistin resistance in *E. coli* increased from (total number of *E. coli* isolates) 0.4% in 2012 ($n = 13,221$), to 0.8% in 2014 ($n = 18,244$) ($P < 0.001$). During 2015, the National Strategy for the Control of Antimicrobial Resistance was implemented in our country. However, the current information about antimicrobial resistance in veterinary medicine, animal production, and food production is scarce. At the NRLAR, we issued a regional alert on 2 February 2016, warning about the emergence of *mcr-1*-mediated colistin resistance in clinical isolates from Argentina, and released guidelines for active surveillance by health care providers. By 9 March 2016, 10 additional colistin-resistant *E. coli* isolates from six new hospitals had been submitted to the NRLAR and confirmed as *mcr-1* positive. The finding of *mcr-1* in *E. coli* clinical isolates is probably the tip of the iceberg that is a big hidden health issue in South America.

Accepted manuscript posted online 18 April 2016

Citation Rapoport M, Faccione D, Pasteran F, Ceriana F, Albornoz E, Petroni A, MCR Group, Corso A. 2016. First description of *mcr-1*-mediated colistin resistance in human infections caused by *Escherichia coli* in Latin America. *Antimicrob Agents Chemother* 60:4412–4413. doi:10.1128/AAC.00573-16.

Address correspondence to Alejandra Corso, acorso@anlis.gov.ar.

‡ See Acknowledgments for members of the MRC Group.

Copyright © 2016, American Society for Microbiology. All Rights Reserved.

ACKNOWLEDGMENTS

The MCR Group includes the following: María Laura Maldonado and Celeste Lucero, NRLAR, INEI-ANLIS Dr. C. Malbrán, Buenos Aires, Argentina; Flavia Amalfa, Hospital General de Agudos Parmenio Piñero, Buenos Aires City, Argentina; Maria Susana Aiassa, Hospital Córdoba, Córdoba, Argentina; Laura Errecalde and Sara Kauffman, Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires City, Argentina; Manuel Arturo López, Hospital Luis Carlos Lagomaggiore, Mendoza, Argentina; Andrea Vila and Hugo Pagella, Hospital Italiano de Mendoza, Mendoza, Argentina; and Graciela Greco, Hospital Italiano, Buenos Aires City, Argentina.

We have no competing interests to declare.

FUNDING INFORMATION

This work was supported by the regular federal budget of the National Ministry of Health of Argentina.

REFERENCES

- Liu Y-Y, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis* 16:161–168. [http://dx.doi.org/10.1016/S1473-3099\(15\)00424-7](http://dx.doi.org/10.1016/S1473-3099(15)00424-7).
- Du H, Chen L, Tang YW, Kreiswirth BN. 2016. Emergence of the *mcr-1* colistin resistance gene in carbapenem-resistant *Enterobacteriaceae*. *Lancet Infect Dis* 16:287–288. [http://dx.doi.org/10.1016/S1473-3099\(16\)00056-6](http://dx.doi.org/10.1016/S1473-3099(16)00056-6).
- Olaitan AO, Chabou S, Okdah L, Morand S, Rolain JM. 2016. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 16:147. [http://dx.doi.org/10.1016/S1473-3099\(15\)00540-X](http://dx.doi.org/10.1016/S1473-3099(15)00540-X).
- Arcilla MS, van Hattem JM, Matamoros S, Melles DC, Penders J, de Jong MD, Schultsz C, COMBAT Consortium. 2016. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 16:147–149. [http://dx.doi.org/10.1016/S1473-3099\(15\)00541-1](http://dx.doi.org/10.1016/S1473-3099(15)00541-1).
- Skov RL, Monnet DL. 2016. Plasmid-mediated colistin resistance (*mcr-1* gene): three months later, the story unfolds. *Euro Surveill* 21:30155. <http://dx.doi.org/10.2807/1560-7917.ES.2016.21.9.30155>.
- Hindler JA, Humphries RM. 2013. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli. *J Clin Microbiol* 51:1678–1684. <http://dx.doi.org/10.1128/JCM.03385-12>.
- Gomez SA, Pasteran FG, Faccone D, Tijet N, Rapoport M, Lucero C, Lastovetska O, Alborno E, Galas M, Group KPC, Melano RG, Corso A, Petroni A. 2011. Clonal dissemination of *Klebsiella pneumoniae* ST258 harbouring KPC-2 in Argentina. *Clin Microbiol Infect* 17:1520–1524. <http://dx.doi.org/10.1111/j.1469-0691.2011.03600.x>.

TABLE 1 Characteristics of *mcr-1*-harbouring *E. coli* isolates

Characteristic	<i>E. coli</i> isolate:										<i>Salmonella</i> sp. strain TC-M19736
Characteristic	M15049	M15224	M17059	M17056	M19241	M19242	M19441	M19736	M19855		
Isolation date	July 2012	Oct. 2012	Nov. 2013	Nov. 2013	Mar. 2015	Apr. 2015	July 2015	Nov. 2015	Jan. 2016		
Diagnostic/underlying disease of patient	Neurologic disease	Diabetes	Appendicitis	Urinary tract infection	Prostate cancer	Heart failure	Rheumatoid arthritis	Secondary peritonitis/colon cancer	NA ^a		
Isolation site	Blood	Urine	Abdomen	Blood	Urine (catheter)	Urine (catheter)	Bone	Blood	Blood		
Hospital	1	2	3	3	3	3	4	5	6		
MIC (μ g/ml) ^b of:											
Colistin	8	16	8	8	8	8	8	8	8		16
Polymyxin B	8	16	16	8	8	8	8	8	8		16
Additional resistance(s) ^c	TET, TMS, CIP, FOS	AMP, FGG, NIT, MIN, TMS, CIP, FOS	AMP, AMS, FGG, ESC, GEN, MIN, CIP	AMP, CIP	CIP	AMP, AMS, FGG, ESC, TMS, GEN	AMP, AMS, FGG, ESC, CMP, GEN, MIN, CIP	AMP, AMS, CMP, CIP	AMP, AMS, FGG, ESC, GEN, MIN, CIP		None
ESBL ^d genes	None	None	CTX-M-14 group	None	None	CTX-M-2 group	CTX-M-15 group	None	CTX-M-14 group		

^a NA, not available.

^b Susceptibility to colistin and polymyxin B was evaluated by agar dilution.

^c AMP, ampicillin; AMS, ampicillin-sulbactam; FGG, first-generation cephalosporins; ESC, extended-spectrum cephalosporins; TET, tetracycline; MIN, minocycline; TMS, trimethoprim-sulfamethoxazole; CIP, ciprofloxacin; FOS, fosfomicin; NIT, nitrofurantoin; GEN, gentamicin; CMP, chloramphenicol.

^d ESBL, extended-spectrum β -lactamase.